Fortress Biotech, Inc. (FBIOP) Free cash flow 2016–2024
Fortress Biotech, Inc. (FBIOP) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$80.2MFY2024 · since FY2016: -$52.2M → -$80.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$80.2M | +37.5% |
| FY2023 | -$128.3M | +29.6% |
| FY2022 | -$182.1M | -50.4% |
| FY2021 | -$121.1M | -41.5% |
| FY2020 | -$85.6M | +12.0% |
| FY2019 | -$97.3M | +8.1% |
| FY2018 | -$105.9M | -29.3% |
| FY2017 | -$82.0M | -57.1% |
| FY2016 | -$52.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More FBIOP financial trends
FBIOP RevenueFBIOP Net incomeFBIOP Net marginFBIOP Gross profitFBIOP Gross marginFBIOP Operating incomeFBIOP Operating marginFBIOP Operating cash flowFBIOP Capital expendituresFBIOP Return on equityFBIOP Stock buybacksFBIOP Dividends paidFBIOP Total assetsFBIOP Total liabilitiesFBIOP Shareholders’ equityFBIOP overview →